Our Mission
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
News Releases
Year
News Releases
- Dec. 7, 2012 - Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CtrC-AACR San Antonio Breast Cancer Symposium Read
- Nov. 14, 2012 - Puma Biotechnology Reports Third Quarter 2012 Financial Results Read
- Nov. 7, 2012 - Puma Biotechnology to Present at Lazard Healthcare Conference Read
- Oct. 24, 2012 - Puma Biotechnology Closes $138 Million Public Offering of Common Stock Read
- Oct. 22, 2012 - Puma Biotechnology Announces Underwriters' Full Exercise of Overallotment Option, Increasing Total Offering Size to $138 Million Read
- Oct. 18, 2012 - Puma Biotechnology Announces Upsizing and Pricing of $120 Million Public Offering of Common Stock Read
- Sept. 12, 2012 - Puma Biotechnology to Present at UBS Global Life Sciences Conference Read
- Aug. 29, 2012 - Puma Biotechnology to Present at Stifel Nicolaus 2012 Healthcare Conference Read
- Aug. 14, 2012 - Puma Biotechnology Reports Second Quarter 2012 Financial Results Read
- Aug. 7, 2012 - Puma Biotechnology to Present at Wedbush PacGrow Life Sciences Conference Read
- June 2, 2012 - Puma Biotechnology Presents Positive PB272 Clinical Data at ASCO 2012 Annual Meeting Read
- May 30, 2012 - Puma Biotechnology to Present at Jefferies Healthcare Conference Read
- May 17, 2012 - Puma Biotechnology to Present Clinical Data on PB272 at ASCO 2012 Annual Meeting Read
- May 9, 2012 - Puma Biotechnology to Present at BofA Merrill Lynch Health Care Conference Read
- April 16, 2012 - Puma Biotechnology Cleared for Quotation on OTCBB and OTC LINK Read
- Feb. 28, 2012 - Puma Biotechnology to Present at Cowen Health Care Conference Read
- Feb. 9, 2012 - Puma Biotechnology to Present at Leerink Swann Global Healthcare Conference Read
- Jan. 4, 2012 - Puma Biotechnology to Present at 30th Annual J.P. Morgan Healthcare Conference Read